Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jul 27;62(8):e00616-18.
doi: 10.1128/AAC.00616-18. Print 2018 Aug.

Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis"

Claudio U Köser  1   2 , Jan Heyckendorf  3   4   5 , Sönke Andres  6 , Ioana D Olaru  3   4 , Thomas Schön  7   8 , Erik Sturegård  9 , Patrick Beckert  2   4 , Viola Schleusener  2 , Thomas A Kohl  2   4 , Doris Hillemann  6 , Danesh Moradigaravand  10 , Julian Parkhill  10 , Sharon J Peacock  1   10   11 , Stefan Niemann  2   4 , Christoph Lange  12   4   5   13 , Matthias Merker  2   4
Affiliations
Comment

Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis"

Claudio U Köser et al. Antimicrob Agents Chemother. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Heyckendorf J, Andres S, Köser CU, Olaru ID, Schön T, Sturegard E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M. 2018. What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi- and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 62:e01550-17. doi:10.1128/AAC.01550-17. - DOI - PMC - PubMed
    1. Dookie N, Naidoo K, Padayatchi N. 2018. Whole-genome sequencing to guide the selection of treatment for drug-resistant tuberculosis. Antimicrob Agents Chemother 62:e00574-18. doi:10.1128/AAC.00574-18. - DOI - PMC - PubMed
    1. Ajileye A, Alvarez N, Merker M, Walker TM, Akter S, Brown K, Moradigaravand D, Schön T, Andres S, Schleusener V, Omar SV, Coll F, Huang H, Diel R, Ismail N, Parkhill J, de Jong BC, Peto TE, Crook DW, Niemann S, Robledo J, Smith EG, Peacock SJ, Köser CU. 2017. Some synonymous and nonsynonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-positive fluoroquinolone resistance results with the Hain GenoType MTBDRsl assays. Antimicrob Agents Chemother 61:e02169-16. doi:10.1128/AAC.02169-16. - DOI - PMC - PubMed
    1. World Health Organization. 2018. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis [WHO/CDS/TB/2018.5]. World Health Organization, Geneva, Switzerland: http://apps.who.int/iris/bitstream/10665/260470/1/WHO-CDS-TB-2018.5-eng.pdf.